Compare BMRN & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMRN | CRL |
|---|---|---|
| Founded | 1996 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 13.1B |
| IPO Year | 1999 | 1999 |
| Metric | BMRN | CRL |
|---|---|---|
| Price | $59.87 | $293.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 12 |
| Target Price | $88.22 | ★ $198.27 |
| AVG Volume (30 Days) | ★ 1.7M | 778.8K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | $1,313,646,000.00 | ★ $1,857,601,000.00 |
| Revenue This Year | $15.02 | N/A |
| Revenue Next Year | $12.23 | $3.04 |
| P/E Ratio | $77.32 | ★ N/A |
| Revenue Growth | ★ 17.62 | 10.48 |
| 52 Week Low | $49.26 | $146.20 |
| 52 Week High | $70.98 | $303.31 |
| Indicator | BMRN | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 31.36 | 57.47 |
| Support Level | $58.03 | $267.27 |
| Resistance Level | $60.36 | $303.31 |
| Average True Range (ATR) | 1.43 | 9.73 |
| MACD | -0.71 | 0.52 |
| Stochastic Oscillator | 9.83 | 74.88 |
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.